Theromics Inc. Announces Closing of Oversubscribed $2M Seed Series and Names John Brooks III to Board of Directors
Summary
The closing of our initial funding validates clinicians opinion that additional tools are needed to elevate thermal ablation to front-line therapy," stated Theromics CEO Ronald Murphy. Mr. Brooks noted, "Theromics is developing an exciting new platform with multiple applications in the growing fields of soft tissue ablation and locally directed drug delivery. In addition, all standard microwave, RF, and Irreversible electroporation (IRE) devices can use HeatSYNC, and its chemical properties augment the energy generated from the ablation system. The Companys proprietary HeatSYNC™ gel is based on a protein naturally found in the body and may increase cost-efficiencies and improve outcomes through more focused and patient-centric delivery. Longer-term, Theromics plans to apply its thermal technology for use as an oncolytic intratumoral drug/immunotherapy delivery platform with the potential to enhance efficacy and improve safety profiles of currently approved medicines.